HC Wainwright & Co. Maintains Buy on Krystal Biotech, Raises Price Target to $361

Benzinga Newsdesk www.benzinga.com Positive 85.3%

Neg 0% Neu 0% Pos 85.3%

HC Wainwright & Co. analyst Joseph Pantginis maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $310 to $361.